A
Amir Bahreini
Researcher at University of Pittsburgh
Publications - 19
Citations - 638
Amir Bahreini is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Metastatic breast cancer & Breast cancer. The author has an hindex of 8, co-authored 18 publications receiving 497 citations. Previous affiliations of Amir Bahreini include Isfahan University of Medical Sciences.
Papers
More filters
Journal ArticleDOI
Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions and cell free DNA of breast cancer patients
Peilu Wang,Amir Bahreini,Rekha Gyanchandani,Peter C. Lucas,Ryan J. Hartmaier,Rebecca J. Watters,Amruth Ram Jonnalagadda,Humberto E. Trejo Bittar,Aaron N. Berg,Ronald L. Hamilton,Brenda F. Kurland,Kurt R. Weiss,Aju Mathew,Jose Pablo Leone,Nancy E. Davidson,Marina N. Nikiforova,Adam Brufsky,Tadeu Ambros,Andrew M. Stern,Shannon Puhalla,Adrian V. Lee,Steffi Oesterreich +21 more
TL;DR: ESR1 mutations were detected at very low allele frequencies in some primary breast cancers, and at high allele frequency in metastases, suggesting that in some tumors rare ESR1-mutant clones are enriched by endocrine therapy.
Journal ArticleDOI
Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response
Matthew J. Sikora,Kristine L. Cooper,Amir Bahreini,Soumya Luthra,Guoying Wang,Uma R. Chandran,Nancy E. Davidson,David J. Dabbs,Alana L. Welm,Steffi Oesterreich +9 more
TL;DR: It is observed that ER drives a unique program of gene expression in ILC cells correlates with the ability of tamoxifen to induce growth in these cells, and targeting growth factors using FGFR1 inhibitors may block survival pathways required by ILC and reverse tamoxIFen resistance.
Journal ArticleDOI
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models
Amir Bahreini,Zheqi Li,Peilu Wang,Peilu Wang,Kevin M. Levine,Nilgun Tasdemir,Lan Cao,Lan Cao,Hazel M. Weir,Shannon Puhalla,Nancy E. Davidson,Nancy E. Davidson,Andrew M. Stern,David Chu,Ben Ho Park,Adrian V. Lee,Steffi Oesterreich +16 more
TL;DR: The generation and characterization of genome-edited T47D and MCF7 breast cancer cell lines with the two most common ESR1 mutations are described, revealing ligand-independent growth and endocrine resistance and identifying novel target genes involved in metastasis-associated phenotypes.
Journal ArticleDOI
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
Ryan J. Hartmaier,Ryan J. Hartmaier,Sally E. Trabucco,Nolan Priedigkeit,Jon Chung,Christine A. Parachoniak,P. Vanden Borre,Samantha Morley,Margaret Rosenzweig,Michael E. Goldberg,James Suh,Siraj M. Ali,J.S. Ross,Brian Leyland-Jones,Brandon Young,C Williams,Ben Ho Park,M. Tsai,Barbara Haley,Julio Peguero,Rena D. Callahan,I. Sachelarie,John Cho,Jennifer M. Atkinson,Amir Bahreini,Amir Bahreini,Alison M. Nagle,Shannon Puhalla,Rebecca J. Watters,Z. Erdogan-Yildirim,L. Cao,Steffi Oesterreich,Aju Mathew,Peter C. Lucas,N. E. Davidson,Adam Brufsky,G.M. Frampton,Phillip J. Stephens,Juliann Chmielecki,Adrian V. Lee +39 more
TL;DR: Data indicate that N-terminal ESR1 fusions involving exons 6–7 are a recurrent driver of endocrine therapy resistance and are impervious to ER-targeted therapies.
Journal ArticleDOI
Upregulation of IRS1 enhances IGF1 response in Y537S and D538G ESR1 mutant breast cancer cells
Zheqi Li,Kevin M. Levine,Amir Bahreini,Peilu Wang,David Chu,Ben Ho Park,Steffi Oesterreich,Adrian V. Lee +7 more
TL;DR: A critical role of enhanced IGF1 signaling in ESR1 mutant cell lines is supported, pointing toward a potential for cotargeting IGF1R and ERα in endocrine-resistant breast tumors with mutant E SR1.